Relative timing of IFNα dose in combination cancer immunotherapy alters outcomes CD8α+ DCs exposed to IFNα undergo maturation and lose phagocytic ability Only DCs matured after antigenic tumor debris generation prime long-term immunity Other DC activators also show schedule-dependent synergy with cytotoxic therapies